TD Private Client Wealth LLC Cuts Stake in Pfizer Inc. (NYSE:PFE)

TD Private Client Wealth LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 21.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,899 shares of the biopharmaceutical company's stock after selling 26,813 shares during the period. TD Private Client Wealth LLC's holdings in Pfizer were worth $2,597,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. State Street Corp increased its position in shares of Pfizer by 1.2% during the third quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after buying an additional 3,405,539 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Geode Capital Management LLC boosted its position in shares of Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after purchasing an additional 1,855,419 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after purchasing an additional 6,977,587 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after purchasing an additional 4,726,549 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Bank of America reaffirmed a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Stock Performance

PFE traded down $0.58 during midday trading on Tuesday, reaching $25.56. The company had a trading volume of 47,484,282 shares, compared to its average volume of 36,645,983. The business has a 50-day moving average of $26.15 and a two-hundred day moving average of $27.02. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market cap of $144.96 billion, a P/E ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.